- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BGB-3111 | BGB3111 | Brukinsa® | compound 27b [US9447106]
zanubrutinib is an approved drug (FDA (2019), EMA (2021))
Compound class: Synthetic organic
Comment: Zanubrutinib (BGB-3111) is a potent, selective and irreversible BTK inhibitor that was developed by BeiGene for utility in the treatment of B cell cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [1-2].
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Robak P, Robak T. (2017)
Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Expert Opin Investig Drugs, 26 (11): 1249-1265. [PMID:28942659]
2. Thompson PA, Burger JA. (2018)
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Expert Opin Investig Drugs, 27 (1): 31-42. [PMID:29125406]
3. Wang Z, Guo Y. (2016)
Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators.
Patent number: US9447106B2. Assignee: Beigene Ltd.. Priority date: 25/04/2013. Publication date: 20/09/2016.